Back to the main directory
EarningsReview / Equity
- AstraZeneca - Buy/SEK 1,656: Guidance worries overdone by Nordea
- Fenix Outdoor - Buy/SEK 1,100: Gaining traction in the US by Nordea
- Investment Daily 10/02/2023 by BNP Paribas Exane
- Enel pre-release FY22 earnings - Slightly ahead by BNP Paribas Exane
- Shield Therapeutics - Strategic year-end pivot sets tone for robust FY23 by Edison Investment Research
- EQUINOR –ESG feedback on results & capital markets update: ESG strategy lless formalised than its peers, but an interesting lead on offshore wind by Oddo BHF
- BYD (002594 CH/1211 HK) by HSBC
- Keeping the Farm but Still Betting the Ranch by BNP Paribas Exane
- EQUITA SIM: ENEL (BUY; Unchanged) - 2022 Preliminary Results by Equita Sim
- 中国科技行业 by HSBC
- Better dividend points to another strong year by BNP Paribas Exane
- Advanced Info Service (ADVANC TB) by HSBC
- Impressive but expensive by BNP Paribas Exane
- A delayed recovery by BNP Paribas Exane
- paragon - Risk reduction should relieve the equity rating by Edison Investment Research
- Improving narrative but more pipeline still needed by BNP Paribas Exane
- Kakao (035720 KS) by HSBC
- Tokmanni - Lower risks in margin development by Danske Bank Equity Research
- Adizero by BNP Paribas Exane
- Looking Like a Not So Goodyear by BNP Paribas Exane
- Schibsted (Buy, TP: NOK250.00) - Q4 beat, but a soft mix by DnB Markets
- Scatec (Sell, TP: NOK56.00) - Debt market confirms higher cost of capital by DnB Markets
- Volvo Cars (Hold, TP: SEK53.00) - Turning point for volume, not margins by DnB Markets
- Carasent (Buy, TP: NOK35.00) - Focus on growth in core markets by DnB Markets
- GN Group (Buy, TP: DKK250.00) - Rights issue a misstep by DnB Markets